Print Friendly, PDF & Email

NCT/Study#

NCT02954523 /

CA180-618

Phase I/II Study of Dasatinib and Osimertinib (AZD9291) in Patients With Advanced Non-small Cell Lung Cancer With EGFR Mutations

DISEASE GROUP:

Phase 1 (Thoracic)

current phase:

Phase I/II

STUDY STATUS:

Accepting Patients

Location:

Hackensack, NJ

For More information:

Call 201-518-3587